Exscientia

Overview

Recursion is an AI-driven drug discovery and development company that leverages machine learning and automation to identify novel targets and design optimized molecules. The company aims to reduce the failure rate and accelerate the timeline of traditional drug discovery by decoding biological processes.

Key Features

• AI-driven Drug Discovery Platform — The Recursion OS platform integrates data, machine learning models, and computational power to streamline the drug discovery process from hit identification to IND-enabling studies.
• Proprietary Biological and Chemical Datasets — Recursion has generated over 50 petabytes of fit-for-purpose data, including phenomics, transcriptomics, proteomics, ADME, and de-identified patient data.
• Automated Wet Lab — The company utilizes robotics and computer vision in its automated wet lab to conduct millions of cell experiments weekly, feeding results back into the Recursion OS.
• Advanced Pipeline — Recursion's platform has yielded a pipeline of potential first-in-class and best-in-class treatments for conditions such as aggressive cancers and rare diseases.
• Strategic Partnerships — Recursion collaborates with pharmaceutical leaders, technology companies, and data partners to accelerate drug discovery and expand its impact.
• BioHive-2 Supercomputer — In partnership with NVIDIA, Recursion built BioHive-2, a powerful supercomputer designed to process its extensive biological and chemical datasets.

Who It's For

Recursion's services are for pharmaceutical companies, biotechnology firms, and research institutions seeking to integrate AI and machine learning into their drug discovery and development pipelines. It targets organizations looking to improve the efficiency, speed, and cost-effectiveness of identifying and developing new therapeutic candidates, particularly for oncology and rare diseases.

Notable Strengths

Recursion's notable strength lies in its integrated approach, combining a large-scale proprietary dataset with an automated wet lab and a powerful AI platform (Recursion OS). This infrastructure has demonstrated improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages. The collaboration with NVIDIA to build the BioHive-2 supercomputer further underscores its commitment to leveraging advanced computational power for drug discovery.